Article Synopsis
- Systemic antiplatelet treatment has the potential to enhance chemotherapy and immunotherapy by addressing the role of platelets in tumor growth and spread.
- Previous attempts to target platelets for cancer therapy faced issues like increased bleeding risks due to non-specific effects on normal platelets.
- Recent research has improved our understanding of how platelets interact with tumors, leading to new approaches for using antiplatelet therapies safely in cancer treatment and monitoring.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Systemic antiplatelet treatment represents a promising option to improve the therapeutic outcomes and therapeutic efficacy of chemotherapy and immunotherapy due to the critical contribution of platelets to tumour progression. However, until recently, targeting platelets as a cancer therapeutic has been hampered by the elevated risk of haemorrhagic and thrombocytopenic (low platelet count) complications owing to the lack of specificity for tumour-associated platelets. Recent work has advanced our understanding of the molecular mechanisms responsible for the contribution of platelets to tumour progression and metastasis. This has led to the identification of the biological changes in platelets in the presence of tumours, the complex interactions between platelets and tumour cells during tumour progression, and the effects of platelets on antitumour therapeutic response. In this Review, we present a detailed picture of the dynamic roles of platelets in tumour development and progression as well as their use in diagnosis, prognosis and monitoring response to therapy. We also provide our view on how to overcome challenges faced by the development of precise antiplatelet strategies for safe and efficient clinical cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41568-023-00639-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PDGFR mediates lumbar spinal stenosis-induced neuropathic pain by regulating JAK2/STAT3 signaling in activated macrophages.
Prog Neurobiol
September 2025
Age-Related and Brain Diseases Research Center, School of Medicine, Kyung Hee University, Seoul, Republic of Korea; Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul, Republic of Korea; Biomedical Science Institute, Kyung Hee University, Seoul, Republi
Lumbar spinal stenosis (LSS) is one of the most common spinal disorders in elderly people and is often accompanied by neuropathic pain. Although our previous studies have demonstrated that infiltrating macrophage contribute to chronic neuropathic pain in LSS rat model, the molecular mechanisms underlying macrophage activation and infiltration have not been fully elucidated. In this study, we examined the critical role of platelet-derived growth factor receptor (PDGFR) signaling pathway in neuropathic pain associated with macrophage infiltration and activation in LSS rats.
View Article and Find Full Text PDFPrognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Colorectal Cancer Survival: A Multicenter Retrospective Cohort Study.
J Gastrointest Cancer
September 2025
Firoozabadi Clinical Research Development Unit (F A CRD U), Iran , University of Medical Sciences (IUMS), Tehran, Iran.
Background: Colorectal cancer (CRC) has become one of the major health burdens in the world with high mortality rates, especially at the advanced stages. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel multidimensional biomarker combining systemic inflammation, nutritional status, and immune function. This study evaluated the association between the CALLY index and overall survival (OS) as well as recurrence-free survival (RFS) in colorectal cancer (CRC) patients.
View Article and Find Full Text PDFPredicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.
Eur J Radiol
September 2025
Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
Objectives: Preoperatively identifying patients with unresectable hepatocellular carcinoma (uHCC) who are likely to achieve an objective response to the treatment regimen of transarterial chemoembolization (TACE) plus lenvatinib and programmed death-1 inhibitors (TLP) remains challenging. We aimed to develop and validate a predictive model for tumor response to TLP treatment in patients with uHCC.
Materials And Methods: Patients with uHCC who received TLP treatment were divided into training (n = 107), internal validation (n = 46), and external validation (n = 52) cohorts.
Repurposing rupatadine to attenuate ovarian ischemia reperfusion in rats through modulation of PAF/NF-κB/TNF-α/IL-1β; HIF-1α/VEGF/Caspase 3 signaling pathways.
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Medical Pharmacology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
The aim of the current study is to identify the possible protective effect of rupatadine (RUP) on ovarian ischemia reperfusion (OIR) in rats. RUP was administered in the presence and absence of OIR. Thirty-two adult Wistar albino female rats were randomly arranged into four groups: Sham, RUP (6 mg/kg/day) for 14 days, OIR and OIR + RUP groups.
View Article and Find Full Text PDFThe persistent residual tumor cells that survive after chemotherapy are a major cause of treatment failure, but their survival mechanisms remain largely elusive. These cancer cells are typically characterized by a quiescent state with suppressed activity of MYC and MTOR. We observed that the MYC-suppressed persistent triple-negative breast cancer (TNBC) cells are metabolically flexible and can upregulate mitochondrial oxidative phosphorylation (OXPHOS) genes and respiratory function ("OXPHOS-high" cell state) in response to DNA-damaging anthracyclines such as doxorubicin, but not to taxanes.
View Article and Find Full Text PDF